Supporting Health Including Endocrine Treatment for Long Duration
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Dana-Farber Cancer Institute
- Study ID
- NCT07482384
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Breast Cancer
- Breast Cancer - Female
- Breast Carcinoma
- ER Positive Breast Cancer
- PR-Positive Breast Cancer
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 49 Years
- Healthy Volunteers
- Not accepted
Interventions
- SHIELD portal — BEHAVIORALAll participants will receive access to the SHIELD portal. The portal includes educational modules, symptom and side effect tracking, tailored informational resources, and health behavior tools. Participants can access the portal via smartphone, tablet, or computer. The portal is HIPAA compliant and HITRUST certified.
Study Details
This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.
Key Dates
- Start date
- May 31, 2026
- Status verified
- Mar 2026
- Primary completion
- Jan 31, 2027
- Completion
- May 31, 2027
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: SHIELD Portal Interventional320 participants will be enrolled and will complete the following: Baseline visit (assessments) either by in-person clinic visit or virtually Follow-Up/Post Baseline (3-month assessments) Medical record review (if necessary)
Primary Outcome Measure
Enrollment Yield [ Time Frame: up to 3 weeks ]
Central Contacts
- Ann H Partridge, MD, MPH617-632-6800
- Kate Dibble, Ph.D.617-582-8294
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 |
Find similar trials in Boston, MA
By condition
By specialty
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast CancerRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast CancerRecruiting · National Cancer Institute (NCI) · Boston, Massachusetts
- Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast CancerRecruiting · National Cancer Institute (NCI) · Boston, Massachusetts